SCHEMBL620472

SCHEMBL620472

C=CC[C@H](C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29854799 1.00
SCHEMBL578574 1.00
SCHEMBL315363 1.00
Ammonia Solution, Strong SCHEMBL169584 0.97
Methylamine SCHEMBL8997149 0.94
Ammonia Solution, Strong SCHEMBL28958150 0.91
Urea SCHEMBL10685728 0.87 GRIK1 (0.38)
SCHEMBL3678694 0.81 TSHR (0.33)
SCHEMBL3678696 0.81 TSHR (0.33)
Alcohol SCHEMBL9844307 0.79 ALDH1A1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 313 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112979605-A Stable isotope labeled zearalenone and synthesis method thereof 上海海关动植物与食品检验检疫技术中心 2021-06-18 CN claimed
EP-4225762-B1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2026-05-27 EP disclosed
US-12612416-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-04-28 US disclosed
EP-4720061-A1 TREM2 AGONISTS F. Hoffmann-La Roche AG (CH) 2026-04-08 EP disclosed
US-12583856-B2 Inhibitors of protein kinase A BLUEPRINT MEDICINES CORPORATION (US) 2026-03-24 US disclosed
US-20260034106-A1 Macrocyclic ligands for FK506-binding proteins for treatment of diseases with improved characteristics UNIV DARMSTADT TECH (DE) 2026-02-05 US disclosed
EP-4686495-A1 MACROCYCLIC LIGANDS FOR FK506-BINDING PROTEINS FOR TREATMENT OF DISEASES WITH IMPROVED CHARACTERISTICS Technische Universität Darmstadt (DE) 2026-02-04 EP disclosed
WO-2025202022-A9 ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 BAYER AKTIENGESELLSCHAFT (DE) 2025-12-26 WO disclosed
US-12486248-B2 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of DHODH BAYER AKTIENGESELLSCHAFT (DE) 2025-12-02 US disclosed
US-20250320226-A1 METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL VERTEX PHARMA (US) 2025-10-16 US disclosed
WO-2000075110-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE TARGACEPT, INC. (US) 2000-12-14 WO disclosed
EP-1056458-A1 METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN Wake Forest University (US) 2000-12-06 EP disclosed
WO-2000062767-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION TARGACEPT, INC. (US) 2000-10-26 WO disclosed
EP-1042274-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE R.J. REYNOLDS TOBACCO COMPANY (US) 2000-10-11 EP disclosed
WO-2000023418-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE R.J. REYNOLDS TOBACCO COMPANY (US) 2000-04-27 WO disclosed
WO-1999065876-A1 ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS R.J. REYNOLDS TOBACCO COMPANY (US) 1999-12-23 WO disclosed
WO-1999043322-A1 METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN WAKE FOREST UNIVERSITY (US) 1999-09-02 WO disclosed
US-4978794-A REACTING WITH AN ALDEHYDE TO FORM OPTICALLY ACTIVE ALCOHOLS ALDRICH CHEMICAL COMPANY, INC. (US) 1990-12-18 US disclosed
US-4225507-A 19-Hydroxy-19-methyl-PGI2 compounds THE UPJOHN COMPANY (US) 1980-09-30 US disclosed
US-4225508-A 19-Hydroxy-PGI2 compounds THE UPJOHN COMPANY (US) 1980-09-30 US disclosed